LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
G.J. Riely(Memorial Sloan Kettering Cancer Center), M-J. Ahn(Samsung Medical Center), Jade Clarke(Duke Medical Center), Ibiayi Dagogo‐Jack(Massachusetts General Hospital), E. Felip(Hebron University), Francesco Gelsomino(Azienda USL di Bologna), J.W. Goldman(University of California, Los Angeles), M. Hussein(Sarah Cannon), M.L. Johnson(Sarah Cannon), D. Morgensztern(Washington University in St. Louis), E. Nadal(Institut Català d'Ornitologia), Michael Offin(Memorial Sloan Kettering Cancer Center), M. Provencio Pulla(Hospital Universitario Puerta de Hierro Majadahonda), S.S. Ramalingam(Emory University), E.F. Smit(Leiden University Medical Center), Anne S. Tsao(The University of Texas MD Anderson Cancer Center), Ann Alcasid(Pfizer (United States)), Tiziana Usari(Pfizer (Italy)), Keith D. Wilner(Pfizer (United States)), Bruce E. Johnson(Dana-Farber Cancer Institute)
Cited by 10Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis